Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 28% Improvement Relative Risk Improvement 26% c19hcq.org Nachega et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 766 patients in DR Congo Lower mortality (p=0.17) and greater improvement (p=0.13), not stat. sig. Nachega et al., The American J. Tropical Medici.., doi:10.4269/ajtmh.20-1240 Favors HCQ Favors control
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo
Nachega et al., The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.20-1240
Nachega et al., Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the.., The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.20-1240
Oct 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 766 hospitalized patients in DRC showing mortality reduced from 29% to 11%, and improvement at 30 days increased from 65% to 84%.
Mortality cox regression adjusted hazard ratio aHR 0.26, p < 0.001
Risk of no improvement adjusted odds ratio aOR 0.28, p < 0.001
Using marginal structural model analysis these risks became:
Mortality MSM adjusted odds ratio aOR 0.65, p = 0.166
Risk of no improvement MSM adjusted odds ratio aOR = 0.65, p = 0.132
Median age 46, 630 treated with CQ+AZ.
Although the 28% lower mortality is not statistically significant, it is consistent with the significant 22% lower mortality [18‑27%] from meta analysis of the 232 mortality results to date.
risk of death, 27.6% lower, RR 0.72, p = 0.17, treatment 69 of 630 (11.0%), control 28 of 96 (29.2%), NNT 5.5, adjusted per study, odds ratio converted to relative risk.
risk of no improvement, 25.8% better, RR 0.74, p = 0.13, adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Nachega et al., 2 Oct 2020, retrospective, database analysis, DR Congo, peer-reviewed, median age 46.0, 25 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit